Across TCGA pan-cancer cohorts, SCRT2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SCRT2’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where SCRT2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SCRT2 is over-expressed in tumor.
STAD, KIRC, and LUSC are the cancer types where SCRT2 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SCRT2 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.